Electronic FRAIL score as a predictor of treatment outcomes in older patients with diffuse large B-cell lymphoma

Zhang, Jesse; Disperati, Patricia; Elinder-Camburn, Anna; Merriman, Eileen; Leitch, Sophie; Chan, Henry

doi:10.1016/j.jgo.2021.12.005

Cited by 1 publication

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5,68,69 The Comprehensive Geriatric Assessment (CGA) is considered the gold-standard method for assessing frailty, [70][71][72][73][74][75] but several other scores have been developed and validated in different haematological malignancies in an attempt to simplify and improve adherence to routine assessment of frailty. [76][77][78][79][80][81][82][83][84][85][86] It would be useful to have a frailty score which was validated across the breath of haematological disease, as this would have the potential to streamline frailty assessment across different diagnoses.…”

Section: Introductionmentioning

confidence: 99%

“…The boundary between frailty and disease can be difficult to delineate, and this is an additional complicating factor when planning treatment for patients 5,68,69 . The Comprehensive Geriatric Assessment (CGA) is considered the gold‐standard method for assessing frailty, 70–75 but several other scores have been developed and validated in different haematological malignancies in an attempt to simplify and improve adherence to routine assessment of frailty 76–86 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Haemato‐Oncology Frailty (HOF) score to assess frailty in lymphoma

Ramdany,

Lofaro,

Deplano

2023

European J of Haematology

View full text Add to dashboard Cite

Morbidity and mortality during chemotherapy in older adults with haematological malignancy can be unpredictable. The Haemato‐Oncology Frailty (HOF) score was previously found to predict outcomes in a cohort of patients with plasma cell myeloma. In this study, we assess its utility in assessing frailty in patients with lymphoma, and compare its performance to that of two other frailty scores. The HOF score was able to predict progression‐free survival in this population, and was also shown to have potential in assessing the dynamism of frailty during chemotherapy. It performed well when compared to the Charlson Comorbidity Index (CCI) score and the Haematopoietic Cell Transplantation‐Specific Comorbidity Index (HCTCI), although the study was not powered to assess for non‐inferiority. The HOF score is a new score with the potential for application in different haematological malignancies.

show abstract